To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Synaptic vesicle protein … - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Synaptic vesicle protein 2A as a potential biomarker in synaptopathies.

Review article
Authors Kerstin Heurling
Nicholas Ashton
Antoine Leuzy
Eduardo R Zimmer
Kaj Blennow
Henrik Zetterberg
Jonas Eriksson
Mark Lubberink
Michael Schöll
Published in Molecular and cellular neurosciences
ISSN 1095-9327
Publication year 2019
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Wallenberg Centre for Molecular and Translational Medicine
Language en
Links dx.doi.org/10.1016/j.mcn.2019.02.00...
www.ncbi.nlm.nih.gov/entrez/query.f...
Subject categories Radiology, Nuclear Medicine and Medical Imaging, Neurosciences, Other Medical Biotechnology

Abstract

Measuring synaptic density in vivo using positron emission tomography (PET) imaging-based biomarkers targeting the synaptic vesicle protein 2A (SV2A) has received much attention recently due to its potential research and clinical applications in synaptopathies, including neurodegenerative and psychiatric diseases. Fluid-based biomarkers in proteinopathies have previously been suggested to provide information on pathology and disease status that is complementary to PET-based measures, and the same can be hypothesized with respect to SV2A. This review provides an overview of the current state of SV2A PET imaging as a biomarker of synaptic density, the potential role of fluid-based biomarkers for SV2A, and related future perspectives.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?